NOTE

🌱 created from: head_and_neck_squamous_cell_cancer

role_of_induction_chemotherapy-of-hnscc

• Rationale:
  • ↓ sxs a/w 1° tumor size, organ preservation, ↓ risk of distant mets;
  • controversial as
    • ↑ duration of tx
    • potential ↑ tox risk
    • no trials have yet shown OS advantage of induction + CRT vs. CRT alone
• If induction chosen, docetaxel, CIS, 5-FU standard
  • (EORTC 24971/TAX 323 NEJM 2007;357:1695)
  • TPF
  • RTOG 91-11

大部分在 induction 加入 CCRT 都沒有 OS 的優勢，唯一有的 trial 有顯著，control arm 的 locoregional control 都比較差